Medical device and MedTech insights, news, tips and more
Serpex Medical Announces Second FDA 510(k) Clearance of Its Steerable Endobronchial Instrument Platform – The Compass Steerable Needle
September 8, 2022
Serpex Medical announced U.S. FDA 510(k) clearance of its Compass Steerable Needles – steerable biopsy needles that enable precise access to lung nodules in the intrapulmonary region. Serpex Medical seeks to leverage the power of steerable instruments to enable greater precision and access to improve the diagnosis and treatment of lung cancer. The clearance of the Compass Steerable Needles follows the recent clearance of Serpex’s Recon Steerable Sheath.
“The Compass steerable needle is a much-needed innovation,” says interventional pulmonologist Dr. George Cheng. “It provides exceptional maneuverability that will enable us to more precisely target and access lesions, at a nominal cost. It’s also agnostic in design, so it can be paired with any navigation platform. It is just what we needed.”
Lung cancer is the world’s leading cause of cancer deaths. Many suspicious lesions found in the lung may be small and difficult to access, which can make diagnosing lung cancer challenging. The slim articulating Compass Steerable Needles provide precise three-dimensional positioning for enhanced reach to all 18 segments of the lung and access to small lesions outside of the airways. The device design allows for a controlled approach to target locations and the ability to sample from multiple aspects of the tumor without unwanted tip deflection, addressing challenging aspects of lung biopsy.
“Precision is essential for confidence in diagnosing lung cancer, especially out in the lung periphery,” says Sasha Schrode, President and Chief Executive Officer of Serpex Medical. “We are excited to deliver another innovative product that empowers clinicians to more successfully diagnose lung cancer at an earlier stage.”
“This is another significant milestone in the team’s pursuit of practical, intuitive innovation,” says Duke Rohlen, Executive Chairman of Serpex Medical and Chief Executive Officer of Ajax Health & Zeus Health. “Now with two sets of clearances, Serpex is poised to make a significant impact on the standard of care for patients with lung cancer.”
Serpex Medical is backed by Ajax Health, Zeus Health, Aperture Venture Partners and Western Technology Investment.
About Serpex Medical
Serpex Medical is based in Santa Clara, California and is developing innovative steerable technology that will enable greater precision while targeting difficult-to-reach lung nodules, especially those outside of the airway.
See Full Press Release at the Source: Serpex Medical Announces Second FDA 510(k) Clearance of Its Steerable Endobronchial Instrument Platform – The Compass Steerable Needle
Press Release by: Serpex Medical
Legacy MedSearch has more than 35 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 17 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.
We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.
Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.